MMedication Read More PBS dispute could see MS patients pay thousands for crucial drugs Ocrevus and KesimptaJuly 7, 2026 A dispute over how Australia prices medicines has sparked fears 10,000 people with multiple sclerosis will be forced…
HHealthcare Read More Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patientsFebruary 27, 2026 Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
HHealthcare Read More Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patientsFebruary 25, 2026 Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite…
MMedication Read More Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)February 21, 2026 Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
HHealthcare Read More Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discoveryFebruary 7, 2026 New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
HHealthcare Read More Novartis and US government reach agreement on lowering drug prices in the USDecember 20, 2025 Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
GGenetics Read More One in four Indians faces silent genetic threat to heart health, shows studySeptember 24, 2025 In the Asia Pacific and Middle East region, two in three individuals (66%) skip routine heart tests, while…
HHealthcare Read More AI Tools Are Spreading Medical Scams OnlineSeptember 11, 2025 In this week’s edition of InnovationRx, we look at AI medical scams, using machine learning to derive drugs…